Context Therapeutics (CNTX) Return on Capital Employed (2021 - 2026)

Context Therapeutics has disclosed Return on Capital Employed across 6 years of filings, most recently posting 76.16% for Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 76.16%, down 4238.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 76.16% (down 4238.0% YoY), and the FY2025 annual result was 52.73%, up 233.0% from the prior year.
• Return on Capital Employed came in at 76.16% for Q1 2026 at Context Therapeutics, down from 60.3% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 27.6% in Q1 2022 to a low of 203.03% in Q1 2024.
• The 5-year median for Return on Capital Employed is 41.78% (2022), against an average of 64.78%.
• Across the five-year window, Return on Capital Employed slumped 14440 bps in 2024 and surged 16926 bps in 2025, its largest moves.
• Context Therapeutics' Return on Capital Employed stood at 41.78% in 2022, then tumbled by 291 bps to 163.51% in 2023, then surged by 80 bps to 33.44% in 2024, then plunged by 80 bps to 60.3% in 2025, then dropped by 26 bps to 76.16% in 2026.
• The last three Return on Capital Employed figures came in at 76.16% (Q1 2026), 60.3% (Q4 2025), and 39.15% (Q3 2025), per Business Quant data.